caa a22 4500 397592485 CHVBK 20180308164942.0 cr unu---uuuuu 161202e199612 xx s 000 0 eng 10.1093/jac/38.6.1023 doi (NATIONALLICENCE)oxford-10.1093/jac/38.6.1023 The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects [Elektronische Daten] [N. J. Bron, M. B. Dorr, T. G. Mant, C. L. Webb, A. B. Vassos] The single-dose tolerance and pharmacokinetics of clinafloxacin, a new fluoroquinolone antibacterial agent, were evaluated in healthy volunteers. Single oral doses of 25, 50, 100, and 200 mg were well tolerated. Adverse events after placebo and clinafloxacin were similar, with mild drowsiness, dizziness, headache, and rash being reported most frequently. The frequency and intensity of side-effects did not increase with dose. Clinafloxacin was rapidly absorbed, with Cmax, occurring at approximately 40 min postdose. Plasma concentrations increased proportionately and, following 100 or 200 mg doses, remained above MIC90s required for most nosocomial pathogens for at least 12 h. Clinafloxacin elimination half-life averaged 5.2 h and renal clearance was approximately 200 mL/min. About 50% of the administered dose was excreted unchanged in the urine. © 1996 by the British Society for Antimicrobial Chemotherapy Original articles nationallicence Bron N. J. Department of Clinical Pharmacology Division of Warner-Lambert Company, Eastleigh, SO 53 3ZQ; and Ann Arbor, MI 48106-1047, USA aut Dorr M. B. Department of Clinical Pharmacology Division of Warner-Lambert Company, Eastleigh, SO 53 3ZQ; and Ann Arbor, MI 48106-1047, USA aut Mant T. G. Guy's Drug Research Unit London SEl 1YR, UK aut Webb C. L. Department of Clinical Pharmacology Division of Warner-Lambert Company, Eastleigh, SO 53 3ZQ; and Ann Arbor, MI 48106-1047, USA aut Vassos A. B. Department of Clinical Pharmacology Division of Warner-Lambert Company, Eastleigh, SO 53 3ZQ; and Ann Arbor, MI 48106-1047, USA aut Journal of Antimicrobial Chemotherapy Oxford University Press 38/6(1996-12), 1023-1029 0305-7453 38:6<1023 1996 38 jac https://doi.org/10.1093/jac/38.6.1023 text/html Onlinezugriff via DOI 1 other jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/38.6.1023 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bron N. J. Department of Clinical Pharmacology Division of Warner-Lambert Company, Eastleigh, SO 53 3ZQ; and Ann Arbor, MI 48106-1047, USA aut NATIONALLICENCE 700 1- Dorr M. B. Department of Clinical Pharmacology Division of Warner-Lambert Company, Eastleigh, SO 53 3ZQ; and Ann Arbor, MI 48106-1047, USA aut NATIONALLICENCE 700 1- Mant T. G. Guy's Drug Research Unit London SEl 1YR, UK aut NATIONALLICENCE 700 1- Webb C. L. Department of Clinical Pharmacology Division of Warner-Lambert Company, Eastleigh, SO 53 3ZQ; and Ann Arbor, MI 48106-1047, USA aut NATIONALLICENCE 700 1- Vassos A. B. Department of Clinical Pharmacology Division of Warner-Lambert Company, Eastleigh, SO 53 3ZQ; and Ann Arbor, MI 48106-1047, USA aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 38/6(1996-12), 1023-1029 0305-7453 38:6<1023 1996 38 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford